A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07380412

Enrollment

Registered

2026-02-02

Start date

2025-08-12

Completion date

2026-03-01

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD, Brain Fog, Sleep Disturbance

Keywords

ADHD, Anxiety

Brief summary

This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults.

Interventions

DIETARY_SUPPLEMENTStasis Daytime and Nighttime

Daytime taken with stimulant medication and food. Nighttime taken 30 minutes before bedtime on an empty stomach.

DIETARY_SUPPLEMENTPlacebo

Matched placebo product in taste and appearance.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Triple (Participant, Care Provider, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Aged 18-55 years * Currently prescribed stimulant medication for ADHD * Experiencing: sleep difficulty, irritability, anxiety, brain fog * Stable medication dose ≥3 months * Healthy with no uncontrolled chronic conditions * Stable on supplements ≥3 months if applicable * US resident * Willing to maintain current habits

Exclusion criteria

* Chronic conditions (e.g. cancer, mental illness) * Use of psychiatric medications besides stimulants * Pregnancy, breastfeeding, thyroid, liver, kidney conditions * Recent smokers or heavy alcohol use * Night shift workers * Participation in other clinical trials * Allergies to product ingredients

Design outcomes

Primary

Measure	Time frame	Description
Change in oxidative stress and cortisol levels as measured by hs-CRP, 8-OHdG	Baseline and Month 3	Measurement of oxidative stress and cortisol levels will be assessed using the following validated biomarkers: hs-CRP and serum cortisol from blood samples 8-hydroxy-2'-deoxyguanosine (8-OHdG) from urine samples
Change in cortisol levels	Baseline and Month 3	Serum cortisol concentration measured via blood draw.

Secondary

Measure	Time frame	Description
Change in sleep quality	Baseline, Month 1, Month 2, and Month 3	Sleep quality assessed via self-report questionnaire.
Change in irritability	Baseline, Month 1, Month 2, and Month 3	Irritability assessed via self-report questionnaire.
Change in focus	Baseline, Month 1, Month 2, and Month 3	Focus assessed via self-report questionnaire.
Change in sociability	Baseline, Month 1, Month 2, and Month 3	Sociability assessed via self-report questionnaire.
Change in self-reported mood	Baseline, Month 1, Month 2, and Month 3	Mood assessed via self-report questionnaire.
Change in self-reported stress	Baseline, Month 1, Month 2, and Month 3	Stress levels assessed via self-report questionnaire.
Change in self-reported appetite	Baseline, Month 1, Month 2, and Month 3	Appetite assessed via self-report questionnaire.
Change in blood levels of Vitamin C	Baseline and Month 3	Serum levels of Vitamin C measured via blood test.
Change in blood levels of CoQ10	Baseline and Month 3	Serum levels of Coenzyme Q10 measured via blood test.

Countries

United States

Contacts

CONTACTPatrick Renner, MSc

hello@citruslabs.com4242450284

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026